C4 Therapeutics
Stock Forecast, Prediction & Price Target
C4 Therapeutics (CCCC) stock Price Target by analysts
$16
Potential upside: 483.94%
C4 Therapeutics price prediction
What is C4 Therapeutics stock analysts` prediction?
C4 Therapeutics stock forecast: Based on 2 Wall Street analysts` predicted price targets for C4 Therapeutics in the last 3 months, the avarage price target is $16, with a high forecast of $NaN. The average price target represents a 483.94% change from the last price of $2.74.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
C4 Therapeutics stock Price Target by analysts
Full breakdown of analysts given C4 Therapeutics price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Derek Archila Wells Fargo | 0% 0/1 | 9 months ago | $12 337.95% upside | $4.31 | TheFly | Previous targets (0) |
Etzer Darout BMO Capital | 0% 0/1 | 12 months ago | $20 629.92% upside | $6.87 | StreetInsider | Previous targets (0) |
Unknown Wells Fargo | N/A | over 2 years ago | $9 228.46% upside | $6.31 | Benzinga | N/A |
Unknown Credit Suisse | N/A | over 3 years ago | $10 264.96% upside | $8.85 | Benzinga | N/A |
Chi Fong Bank of America Securities | 0% 0/1 | over 3 years ago | $15 447.44% upside | $8.01 | Pulse 2.0 | Previous targets (0) |
C4 Therapeutics Financial Estimates
C4 Therapeutics Revenue Estimates
C4 Therapeutics EBITDA Estimates
C4 Therapeutics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $45.78M N/A | $31.09M -32.08% | $20.75M -33.25% | Avg: $16.86M Low: $13.39M High: $18.69M avg. -18.74% | Avg: $91.38M Low: $44.50M High: $130.46M avg. 441.85% | Avg: $1.50B Low: $732.99M High: $2.14B avg. 1546.87% | Avg: $4.32B Low: $2.10B High: $6.16B avg. 187.08% |
Net Income
% change YoY
| $-86.03M N/A | $-126.49M -47.02% | $-132.49M -4.73% | Avg: $-149.06M Low: $-153.88M High: $-67.01M avg. -12.50% | Avg: $-129.4M Low: $-72.97M High: $-34.25M avg. 13.18% | Avg: $208.98M Low: $69.63M High: $325.19M avg. 261.50% | Avg: $740.13M Low: $246.60M High: $1.15B avg. 254.15% |
EBITDA
% change YoY
| $-80.25M N/A | $-125.95M -56.94% | $-122.10M 3.06% | Avg: $-16.86M Low: $-18.69M High: $-13.39M avg. 86.18% | Avg: $-91.38M Low: $-130.46M High: $-44.50M avg. -441.85% | Avg: $-1.50B Low: $-2.14B High: $-732.99M avg. -1546.87% | Avg: $-4.32B Low: $-6.16B High: $-2.10B avg. -187.08% |
EPS
% change YoY
| -$1.87 N/A | -$2.59 -38.50% | -$2.67 -3.08% | Avg: -$1.91 Low: -$3.1 High: -$1.35 avg. 28.62% | Avg: -$1.23 Low: -$1.47 High: -$0.69 avg. 35.35% | Avg: $4.21 Low: $1.4 High: $6.55 avg. 441.72% | Avg: $14.91 Low: $4.97 High: $23.2 avg. 254.15% |
Operating Expenses
% change YoY
| $127.91M N/A | $160.63M 25.57% | $159.78M -0.52% | Avg: $15.60M Low: $12.38M High: $17.29M avg. -90.23% | Avg: $84.53M Low: $41.17M High: $120.69M avg. 441.85% | Avg: $1.39B Low: $678.07M High: $1.98B avg. 1546.87% | Avg: $3.99B Low: $1.94B High: $5.70B avg. 187.08% |
FAQ
What is C4 Therapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 129.08% in 2025-2028.
We have gathered data from 6 analysts. Their low estimate is -153.88M, average is -149.06M and high is -67.01M.
What is C4 Therapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 539.26% in 2025-2028.
We have gathered data from 5 analysts. Their low revenue estimate is $13.39M, average is $16.86M and high is $18.69M.
What is C4 Therapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 189.96% in 2025-2028.
We have gathered data from 6 analysts. Their low earnings per share estimate is -$3.1, average is -$1.91 and high is $-1.35.
What is the best performing analyst?
In the last twelve months 2 analysts have been covering C4 Therapeutics stock. The most successful analyst is Derek Archila.